ArticleMedicine2026
Exploring causal relationships between circulating inflammatory proteins and superficial thrombophlebitis: A Mendelian randomization study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
This study explores the potential causal relationship between circulating inflammatory proteins and superficial thrombophlebitis (STP) using Mendelian randomization (MR). We utilized data on 91 circulating inflammatory proteins from publicly available genome-wide association studies and STP data from the FinnGen consortium's R11 release. The primary analysis method was inverse variance-weighted analysis, complemented by MR-Egger regression and weighted median methods for validation. Additionally, sensitivity analyses and reverse MR tests were conducted to assess the reliability of the results. In the inverse-variance weighted analysis, we observed nominal positive associations between circulating inflammatory proteins, including neurotrophin-3 (NT-3) (OR = 1.132, 95%CI: 1.024-1.252, P = .016), osteoprotegerin (OR = 1.120, 95%CI: 1.013-1.238, P = .027), and vascular endothelial growth factor A (OR = 1.068, 95%CI: 1.008-1.132, P = .027), and the risk of STP (all raw P < .05). Conversely, interleukin-12 subunit beta (OR = 0.917, 95%CI: 0.858-0.980, P = .011) and interleukin-8 (OR = 0.905, 95%CI: 0.824-0.993, P = .035) showed nominal inverse associations with STP risk. However, none of these associations remained statistically significant after Bonferroni or Benjamini-Hochberg FDR correction for multiple testing. Sensitivity analyses showed no significant pleiotropy or heterogeneity, and the effect directions were consistent across complementary MR methods. This hypothesis-generating MR study identified nominal suggestive associations between 5 circulating inflammatory proteins (neurotrophin-3, osteoprotegerin, vascular endothelial growth factor, interleukin-12 subunit beta, and interleukin-8) and STP risk, though none survived correction for multiple testing. These findings provide candidate inflammatory proteins for future validation and underscore the potential role of inflammation in STP pathogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.